Furthermore, the results of proteomics-based survival analysis revealed that high TMED9 expression posed a risk factor for BRCA, GBM, HNSC, KIRC, LUSC, and pancreatic ductal adenocarcinoma (PDAC) (Supplementary Figures 9A–F). Here, TMED9 is linked to glioblastoma.